Pneumococcal Infections, Pneumococcal Pneumonia
Conditions
Keywords
Pneumococcal Infections, Pneumococcal Vaccines, pneumococcal protein
Brief summary
This study was designed to evaluate the safety, tolerability, and immunogenicity of three doses of an investigational pneumococcal vaccine in healthy adult volunteers. Primary Objective: * To evaluate the safety and tolerability of an investigational Pneumococcal vaccine.
Detailed description
Each volunteer participant will receive two injections with one of three vaccine doses, administered on Day 0 and Day 30, in a dose-ascending manner, pending safety review at each dose level. All participants will be monitored for safety for 30 days after each injection.
Interventions
BIOLOGICALPneumococcal Vaccine
0.5 mL, intramuscular
Sponsors
Sanofi
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Aged 18 to 50 years on the day of inclusion * Healthy, as determined by medical history and clinical examination * Informed consent obtained * Able to attend all scheduled visits and to comply with all trial procedures * For a woman, inability to bear a child or negative urine pregnancy test at each vaccination visit * For a woman of child-bearing potential: use of two medically acceptable, effective methods of contraception (oral contraceptive, intrauterine device, diaphragm, spermicide, or condom) or abstinence throughout the study participation starting at least 30 days prior to the first vaccination up to at least 30 days after the last vaccination.
Exclusion criteria
* Serious chronic disease (i.e., cardiac, renal, neurologic, rheumatologic, metabolic, gastrointestinal, psychiatric, or other organ system) that could interfere with trial conduct or and/or raise a safety concern * For a woman, breast-feeding * Participation in another clinical trial in the 30 days preceding the first trial vaccination * Planned participation in another clinical trial during the present trial period * Congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy * Systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances * Current abuse of alcohol or drug addiction that may interfere with the subject's ability to comply with trial procedures * Blood or blood-derived products received in the past 3 months * Any vaccination in the 30 days preceding the first trial vaccination * Vaccination planned in the 30 days following any trial vaccination * Known Human Immunodeficiency Virus (HIV), hepatitis B, or hepatitis C seropositivity * Known thrombocytopenia or bleeding disorder contraindicating intramuscular (IM) vaccination * Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent * Febrile illness (≥ 38.0°C \[or 100.4°F\]) within 72 hours of inclusion/vaccination * Previous vaccination in the preceding 5 years against pneumococcal disease with another vaccine * History of pneumococcal infection (confirmed either clinically, serologically, or microbiologically) within 5 years * Subject at high risk of pneumococcal infection during the trial * Subjects living in a household with children \< 5 years of age * Antibiotic usage or upper or lower respiratory tract infection within one week before any blood draw for immunogenicity (Visits 1, 3, and 5).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The occurrence of solicited injection site reactions, solicited systemic reactions, unsolicited systemic reactions, and serious adverse events occurring throughout the trial | Day 0 up to Day 60 post vaccination | Solicited injection site reactions: Pain, Erythema, and Swelling. Solicited systemic reactions: Fever (Temperature), Headache, Malaise, and Myalgia |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Immunogenicity of pneumococcal vaccine after 2 vaccinations | Day 0 and 30 days post vaccination | Evaluation of immune responses to antigen component of the investigational vaccine by enzyme linked immunosorbent assay (ELISA). |
Countries
Switzerland
Outcome results
None listed